Skip to main content

Table 1 Model inputs

From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

  Estimates Low High Source
Health state utilities 0.673 0.27 0.80 [16, 17]
Stable disease on oral therapy 0.653 0.26 0.78 [16, 17]
Stable disease on IV therapy 0.473 0.19 0.56 [16, 17]
Progressive disease 0    [16, 17]
Death     
Cost of medical services and drugs (€) 2174.7 1627 3021 [12, 13]
Erlotinib 30 days supply (150 mg) 9.1/mg    [12, 13]
Docetaxel 0.2/mg    [12, 13]
Gemcitabine 368    [12, 13]
Hospitalization at home (day) 422    [12, 13]
Day-ward hospital 557.40    [12, 13]
G-CSF injection (per cycle) 220.53    [12, 13]
Erythropoietin (per injection) 2324    [15]
Palliative care after progression (per month)